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Abstract
Advanced cutaneous T-cell lymphoma (CTCL) is resistant to chemotherapy and presents a major area of medical need. In
view of the known role of microRNAs (miRNAs) in the regulation of cellular signalling, we aimed to identify the functionally
important miRNA species, which regulate apoptosis in CTCL. Using a recently established model in which apoptosis of CTCL
cell lines is induced by Notch-1 inhibition by c-secretase inhibitors (GSIs), we found that miR-122 was significantly increased
in the apoptotic cells. miR-122 up-regulation was not specific for GSI-1 but was also seen during apoptosis induced by
chemotherapies including doxorubicin and proteasome blockers (bortezomib, MG132). miR-122 was not expressed in
quiescent T-cells, but was detectable in CTCL: in lesional skin in mycosis fungoides and in Se ´zary cells purified from
peripheral blood. In situ hybridization results showed that miR-122 was expressed in the malignant T-cell infiltrate and
increased in the advanced stage mycosis fungoides. Surprisingly, miR-122 overexpression decreased the sensitivity to the
chemotherapy-induced apoptosis via a signaling circuit involving the activation of Akt and inhibition of p53. We have also
shown that induction of miR-122 occurred via p53 and that p53 post-transcriptionally up-regulated miR-122. miR-122 is thus
an amplifier of the antiapoptotic Akt/p53 circuit and it is conceivable that a pharmacological intervention in this pathway
may provide basis for novel therapies for CTCL.
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Introduction
Mycosis fungoides (MF) and Se ´zary syndrome (SS) are the
commonest cutaneous T-cell lymphoma (CTCL) [1]. SS is a
lymphoma-leukaemia syndrome characterized by erythroderma
and the presence of a malignant T-cell clone in the peripheral
blood and the skin. Lymphomatous infiltrations in the skin in MF
present initially as patches and plaques that eventually progress to
tumours with subsequent involvement of lymph nodes and visceral
organs [1,2]. Advanced cutaneous T-cell lymphoma is an
incurable disease and represents an area of a high medical need.
Classic anthracycline- or nucleoside analog-based regimens
provide only short-lived responses and relapses are invariably
observed within a year [2,3]. It has been hypothesized that
relapses are caused by a subpopulation of long-lived, mitotically
quiescent malignant cells that survive even intensive chemother-
apy regimes [4]. Current research efforts are therefore concen-
trated on a better understanding of chemotherapy resistance in
CTCL and on identification of new pharmacological targets [3,5].
Notch-1 is an evolutionarily conserved receptor that is
indispensable for the normal T-cell development [6–8]. General
mechanisms involved in Notch-dependent leukemogenesis have
originally been described in acute lymphoblastic T-cell leukaemia
(T-ALL) and include the chromosomal translocation (t (7; 9)) [9]
and gain-of function mutations of Notch-1 [10]. Subsequently,
Notch has been connected with the pathogenesis of several solid
tumours and haematological malignancies [11]. In contrast to the
situation seen in T-ALL, the hyperactivation of Notch-1 in these
neoplasms is not usually mutation-driven but depends on an
excessive proteolytic cleavage by the c-secretase complex [12] that
leads to translocation of the biologically active Notch fragment
into the nucleus. Inhibition of Notch can therefore be achieved by
c-secretase inhibitors (GSIs) and GSI compounds advanced to
phase I clinical trials for refractory T-ALL (www.clinicaltrials.gov/
ct2/show/NCT00100152), breast cancer (www.clinicaltrials.
gov/ct2/show/NCT00106145, www.clinicaltrials.gov/ct2/show/
NCT00645333) and other solid tumours [13]. Recently, we have
provided evidence that Notch-1 is a promising therapeutic target
in CTCL. Notch-1 is expressed in MF, SS, and in CD30
+
cutaneous lymphomas and Notch blockade by GSIs causes
apoptosis in various lymphoma cell lines [14,15].
The major concern associated with the clinical use of GSIs is a
significant organ toxicity at therapeutic doses [16]. We have
therefore studied the mechanisms determining resistance to
chemotherapy in CTCL with a particular focus on microRNA
(miRNA)-mediated regulation. miRNAs are short (222 nt.),
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by targeting mRNAs at the 39 untranslated regions (UTRs)
[17,18]. It is postulated that each miRNA regulates up to 100
different mRNAs and that more than 10,000 mRNAs appear to be
directly regulated by miRNAs [19]. These targeted genes control
fundamental cellular processes such as cell proliferation and
apoptosis [20] and therefore it is not surprising that aberrant
miRNA signalling is associated with cancer initiation and
progression [21]. We have recently investigated the changes in
miRNA expression induced by GSIs and found that several
miRNA species are deregulated in CTCL cell lines [22]. Among
these, we identified miR-122, which has been considered to be
specifically expressed in liver and involved in hepatocarcinogenesis
[23,24]. Since miR-122 has been shown to stimulate hepatocyte
apoptosis, we hypothesized that it plays a similar role in lymphoma
cells and possibly mediates the pro-apoptotic activity of GSI.
Surprisingly, we found that the function of miR-122 is highly tissue
specific and that in malignant T-lymphocytes it blocks apoptosis.
We describe here a negative regulatory loop in which miR-122 is
induced by chemotherapeutic agents via p53 and increases cell
resistance to apoptosis via stimulation of Akt kinase.
Materials and Methods
Ethic Statement
The study was approved by the Ethics Committee of Co-
penhagen and Frederiksberg. Skin biopsies were collected from 21
patients with MF after written informed consent.
Cell culture and tissue procurement
Three CTCL cell lines have been used: MyLa2000 derived
from a plaque biopsy of a patient with MF [25], SeAx [26] and
Hut-78 [27] derived from peripheral blood of patients with Se ´zary
syndrome. MyLa2000 and SeAx cells were cultured in DMEM
containing 4.5 g/l glucose, 10% fetal bovine serum (FBS) and at
37uC under 5% CO2. Hut-78 cells were cultured in RPMI 1640
containing 2 mM L-glutamine and 10% FBS. Human primary T-
cells (CD4
+ and CD8
+, quiescent T-cells) from three healthy
donors were purified using density gradient centrifugation (Ficoll-
PlaqueTM PLUS, Amersham Biosciences, Uppsala, Sweden) as
previously described [15]. Se ´zary cells (CD4
+CD7
2) were isolated
from the peripheral blood of two patients (2 males; age of 56 and
65 years; CD4
+/CD8
+ ratio of 19 and 29) using anti-CD7 biotin
conjugated antibody (eBioscence, San Diego, CA) and anti-CD4
micro beads (Milteny Biotec) together with the anti-Biotin
Multisort Kit (Milteny Biotec, Bergisch Gladbach, Germany), as
described by Marzec et al. [28]. Lesional skin comprising 10
human punch biopsies were collected from patients with MF (6
males and 4 females; mean age 75 years; range 65 to 90 years; 7
plaque/patch (T2) and 3 tumour (T3) stadium) and stored in
RNAlater (Ambion, Austin TX) before proceeding to tissue
homogenization. In situ hybridization (ISH) was performed on
paraffin sections of 11 patients with MF (7 males and 4 females;
mean age 70 years; range 49 to 88 years; 6 plaque/patch (T2) and
5 tumour (T3) stadium). Patient diagnoses were confirmed by an
expert pathologist in accordance with the WHO-EORTC
classification [1,29].
Reagents
GSI-1 (Z-Leu-Leu-Nle-CHO), Ly294002 (2-(4-morpholino)-8-
phenyl-4H-1-benzopyran-4-one), Akt inhibitor X (10-(49-(N-
diethylamino) butyl)-2-chlorophenoxazine, HCl) were from Merck
Calbiochem (Darmstadt, Germany). Nutlin-3a was from Cayman
Chemical (Ann Arbor, MI). Bortezomib (MG341) and MG132
(Z-Leu-Leu-Leu-CHO) were purchased from Selleck (West Pater-
son, NJ) and doxorubicin hydrochloride from Sigma (Aldrich,
St. Louis, MO). Drugs were dissolved in dimethyl sulphoxide
(DMSO). Mock-treated cells were cultured with DMSO at final
concentrations of 0.04–0.2%.
RNA purification
Tissue samples were homogenized using a TissueLyzer II
(Qiagen, Valencia, CA, USA) and processed as previously
described [30]. Briefly, the cells were centrifuged at 600 rpm for
6 minutes and the pellet was washed twice in PBS. Total RNA
(TRNA) and small RNAs were purified using the RneasyH
MiniKit (Qiagen, Hilden, Germany) and mirVana MicroRNA
Isolation Kit (Ambion, Foster City, CA) according to the
manufacturer’s instructions. The concentration of TRNA was
measured spectrophotometrically using NanoDrop ND-1000
(Thermo Scientific, Wilmington, DE), and RNA integrity was
confirmed with Agilent 2100 Bioanalyzer using Agilent Nano
RNA kit (Agilent Technologies, Santa Clara, CA). High quality
total RNA from human liver was from Ambion.
Quantification of miRNA expression by real-time q-PCR
Mature miRNA expression was measured in the samples
containing the same amount of TRNA and small RNAs with
quantitative real-time qRT-PCR assay (TaqMan
TM microRNA
Reverse Transcription kit-4366596, and TaqMan
TM Universal
PCR Master mix-4324018, Applied Biosystems, Foster City, CA)
according to the manufacturer’s instructions. miR-191 was used as
a reference for the normalization of RT-PCR-data [31].
For detection of pri-miR-122, cDNA was prepared from 1 mgo f
TRNA per reaction using High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems) and amplified using
TaqManH Pri-miRNA Assay and TaqManH Gene Expression
Master Mix mix-4324018 (Applied Biosystems) according to the
manufacturer’s instructions. 18S rRNA was used as an internal
control gene.
The RT-PCR was performed in triplicates using a 7900HT Fast
Real-Time PCR System (Applied Biosystems).
In situ hybridization
ISH was done on skin lesions of patients with MF as previously
described [32]. Paraffin sections were mounted on Super-
FrostHPlus slides (Dako, Glostrup, Denmark), air-dried for 1–
2 h at RT, melted in the oven at 60uC for 45 min, deparaffinized
in xylene and hydrated through decreasing ethanol concentra-
tions into PBS. Sections were then treated by proteinase-K
(15 mg/ml in PK-buffer, 5 mM Tris-HCl, pH 7.4, 1 mM EDTA,
1 mM NaCl) at 37uC for 8 min in a volume of 300 mLi naD a k o
hybridizer (Dako), washed, and dehydrated through an increasing
gradient of ethanol solutions. Two different mercury locked
nucleic acid (LNA) miRNA Detection Probes (Exiqon, Vedbaek,
Denmark) were used; hsa-miR-122 (40 nM in a formamide-free
ISH buffer) and scrambled probe (40 nM). Probes were
denatured by heating to 90uC for 4 min and 50 mL probe
mixture was hybridized with the tissue sections in the hybridizer
at 55uC for 60 min. The slides were then placed at RT in 56
saline-sodium citrate (SSC) (Invitrogen) and washed for 5 min at
55uCi n5 6SSC (one wash), 16SSC (two washes) and 0.26SSC
(two washes). After a further washing in PBS, sections were
blocked with DIG Wash and Block Buffer Set (Roche,
Mannheim, Germany) and incubated for 60 min at RT with
alkaline phosphatase (AP)-conjugated anti-DIG (diluted 1:800 in
blocking solution, Roche). Slides were then washed twice with
PBS containing 0.1% Tween-20. Ready to use tablets (Roche) of
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phosphate (BCIP) substrate were dissolved in aqueous 0.2 mM
levamisole. Slides were incubated for 120 min at 30uCt od e v e l o p
the dark-blue NBT-formazan precipitate, washed twice for 5 min
in KTBT buffer (50 mM Tris–HCl, 150 mM NaCl, 10 mM
KCl), and then twice in water, dehydrated in the ethanol gradient
and mounted.
Skin sections were classified into three categories depending on
the percentages (,25%, 25–75%, .75%) of malignant T-cells
positive for miR-122 staining.
siRNA and miRNA Transfection
In the case of SeAx cells, transfection was carried out using
Lipofectamine RNAiMax (Invitrogen, Carlsbad, CA) according to
the manufacturer’s protocol as previously described by [15].
20 nM miRIDIAN miRNA Mimics and Hairpin Inhibitors from
Dharmacon (Thermo Scientific, Chicago, Il) were used for specific
inhibition and overexpression of miR-122. Small Interfering RNA
was used at 50 nM for the specific knockdown of PTEN (6251,
Cell Signalling, Beverly, MA) and p53 (6231, Cell Signalling).
In the case of MyLa2000 cells, transfection was carried out
using 4 ml TurboFect
TM in vitro Transfection Reagent (Fermentas,
Burlington, Canada). 50 nM miRIDIAN miRNA Mimics and
Hairpin Inhibitors from Dharmacon (Thermo Scientific, Chicago,
Il) were mixed to 200 ml GIBCO
TM Opti-MEM I (Invitrogen,
Carlsbad, CA) and incubated for 20 min before application to
500.000 cells/mL.
Scrambled siRNA (Dharmacon) was used as a negative control.
Efficiency of transfection was evaluated by SiGLO (Dharmacon)
and by RT-PCR (Figure S1).
Apoptosis and cell viability
Apoptosis was determined by flow cytometry using FITC-
annexin V/propidium iodide (PI) protocol of the manufacturer
(Beckman Coulter), as previously described [15]. In some
experiments the proportion of viable cells was determined by
staining with only PI (5 mg/ml).
Cells extracts and western blotting
Whole cell extracts were prepared as described previously [15]
and equal amounts of protein were separated by a 12% Bis-Tris
gel electrophoresis at 200 V followed by electrophoretic transfer to
a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA).
Membranes were then blocked for 1 hour at 4uC with Li-Cor
blocking agent (Lincoln, NE), incubated with primary mouse or
rabbit antibody overnight at 4uC followed by incubation for
1 hour with the appropriate secondary antibodies labeled with
800IR dye (anti-rabbit) (Li-Cor) or Alexa Fluor 680 (anti-mouse)
(both from Molecular Probes, Invitrogen Cooperation, Carlsbad,
CA). The following primary antibodies were used: Akt total,
phosphorylated Akt (Ser
473), total FoxO3a, phosphorylated
FoxO3a (Ser
318/321), p53, phosphorylated MDM2 (Ser
166), P70
S6K total and phosphorylated P70 S6K (Thr
421/Ser424) from Cell
Signalling (Beverly, MA), anti–b-actin antibody from Sigma
(Aldrich, St. Louis, MO). Immunoreactivity was detected and
quantified with the infrared Odyssey imaging System (Li-Cor).
Statistics
Continuous data are reported as means with standard deviation
(SD) and the differences were evaluated by the Student’s t-test.
RT-PCR data were analyzed using the DDCT method by paired
Student’s t-test. Normality of the data was assessed by Kolmogor-
off-Smirnov test. Correlation between miR-122 expression level in
the MF biopsies and the stage was analyzed with x
2 test. p-
value,0.05 was considered significant. Statistical analysis was
performed by the SPSS Version 17.0 (SPSS Inc., Chicago, Il),
GraphPad Prism Version 4.03 (GraphPad Software Inc., San
Diego, CA) or Excel (Microsoft Corp., Redmond, WA).
Results
miR-122 is expressed in CTCL and inhibits apoptosis
induced by chemotherapy
In order to identify the miRNA species involved in the
regulation of apoptosis in CTCL, we investigated the influence
of GSIs on miRNA expression pattern in CTCL cell lines. The
rationale for choosing GSIs was our previous studies showing that
these agents potently induce apoptosis via the inhibition of the
proteolytic cleavage of Notch [8,14,15]. Preliminary results
obtained from miRNA arrays were described by Manfe ´ et al.
[22] and revealed miRNA species, differentially expressed between
GSI-1 treated and control cells (miRNAs down-regulated: miR-
27a, miR-92b, miR-181a, miR-18a, miR-425, miR-193b, miR-
30d, miR-199a-5p, miR-19b, miR-222, miR-221, miR-9*, miR-
125a-5p, miR-23b; miRNAs up-regulated: miR-122, miR-214,
miR-185, miR-574-5p, miR-638, miR-149*, miR-766, miR-595).
Subsequent functional analysis using the corresponding antag-
omiRs and mimic oligonucleotides showed a functional signifi-
cance of one of the deregulated miRNAs: miR-122. miR-122 has
been considered to be liver specific but recent evidence showed
that this miRNA is more widely distributed and is also detected in
human skin [30]. Here, we analyzed miR-122 expression by LNA-
ISH in 11 sections of lesional skin biopsies of patients with MF.
Figure 1A shows miR-122 presence in the epidermis and in the
infiltrate of malignant T-cells in plaque/patch (T2) and tumour
(T3) stage MF. LNA-ISH with a control scrambled RNA did not
give any signal (Figure 1A). miR-122 positive signal was
significantly increased in the advanced stage MF (x
2 test, p-
value=0.046); 3 of 5 cases of tumour, but none of the 6 cases of
plaque/patch, displayed more than 75% of malignant T-cells
positive for miR-122 (Figure 1B). We concluded that miR-122
expression correlated with the T-stage in MF.
We also measured miR-122 expression level in vitro and in vivo in
CTCL by TaqMan real-time RT-PCR. As shown in Figure 1C,
miR-122 was not detectable in quiescent-T cells, but it was
expressed in three CTCL cell lines (SeAx, MyLa2000, HuT-78), in
leukaemic cells purified from the patients with Se ´zary syndrome
and in the lesional skin from patients with MF. However, the miR-
122 expression in CTCL was lower than the one in human tissue
liver. Exposure to GSI-1 increased the expression of miR-122 in
SeAx and MyLa2000 cells as previously reported [22], but not in
Hut-78 cells. This effect was not specific to GSI since proteasome
inhibitors (another class of chemotherapeutic agents which induce
apoptosis in CTCL (15)) and doxorubicin increased miR-122
expression in SeAx and MyLa2000 cells (Figure 1D). The
treatment of purified leukaemic Se ´zary cells with GSI-1 also
increased the expression of miR-122 (Figure 1D).
We further examined the effect of miR-122 up-regulation on
apoptosis in CTCL cell lines. We attenuated miR-122 using miR-
122 hairpin inhibitor (antagomiR-122) in GSI-1-treated or
untreated SeAx cells (Figure 2A, B). SeAx treatment with
antagomiR-122, but not with the scrambled oligonucleotide, led
to a substantial increase in apoptosis induced by GSI-1 but did not
affect apoptosis in the untreated cells. mir-122 overexpression had
an opposite effect and protected against GSI-1 induced apoptosis.
We observed similar results with MG132 and bortezomib
(Figure 2C). We also examined the impact of attenuation of
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PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e29541Figure 1. Expression of miR-122 in CTCL. A–B) Analysis of miR-122 expression using ISH and miR-122-specific LNA probe in lesional skin sections
from patients with plaque/patch (n=6) or tumour-stage (n=5) MF. A) Representative ISH staining using miR-122 or scrambled (control) probes in MF
skin sections (plaque/patch-stage MF, left panels; tumour-stage MF, right panels). The blue-purple color indicates miR-122 expression. Magnification:
206and 406. Abbreviation: Epi., epidermis. B) Skin biopsies were classified into three categories depending on the percentages of miR-122 positive
tumour cells, as described in Methods. Comparison of the miR-122 expression profile showed an increase of miR-122 expression in the tumour-stage
MF (p-value=0.046). C) qRT-PCR measurements of miR-122 expression in human liver, in a panel of CTCL cell lines (MyLa2000, SeAx and Hut-78) and
in vivo in leukaemic cells from two patients with Se ´zary syndrome (Se ´zary cells) and in lesional skin from 10 patients with MF. miR-122 expression
levels were normalized to the relative expression in quiescent T-cells. Columns, mean (n=3); bars, SEM. D) Induction of miR-122 during
chemotherapy-induced apoptosis in CTCL cell lines (MyLa2000 SeAx, Hut-78) and in malignant lymphoma cells isolated from peripheral blood of a
patient with Se `zary syndrome (Se ´zary cells). The cells were incubated with 0.8 mM GSI-1, 30 nM MG132, 6 nM bortezomib and 1 mM doxorubicin for 4
and 24 h, as indicated, and miR-122 expression was quantified by qRT-PCR. Because the Se ´zary cells could not be purified in large quantities, the
experiments were only performed with 0.8 mM GSI-1. Data show fold-changes in miR-122 level after treatment as compared to the control, mock-
treated cells. Columns, mean (n=3); bars, SEM. * p-value,0.05 versus untreated cells.
doi:10.1371/journal.pone.0029541.g001
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PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e29541Figure 2. miR-122 increases resistance to GSI-1 and proteasome inhibitors. A) SeAx cells were transfected for 24 h with either scrambled
siRNA (control), miR-122 mimic or antagomiR-122 and treated for 48 h with GSI-1 (0.8 mM) followed by annexin V and propidium iodide staining for
flow cytometry, as described in Methods. The dot-plot graphs (annexin V: green FL1 channel, x-axis; PI: red FL3 channel, y-axis) are representative of
three independent experiments. B–C) Effect of antagomiR-122 and miR-122 mimic on the apoptosis induced by GSI-1 (at the concentrations 0.4, 0.8
and 1.2 mM; 48 h) (B), bortezomib (1, 5, 10 nM; 48 h) (C, left panel) and MG132 (5, 10, 50 nM; 48 h) (C, right panel) in SeAx cells. Cell viability is
expressed as percentage of the PI-negative cells calculated by flow cytometry. Points, mean (n=3); bars, SEM. *p-value,0.05 compared to cells
transfected with scrambled oligonucleotide. D) MyLa2000 cells were transfected for 24 h with either scrambled siRNA (control) or antagomiR-122 and
treated for additional 24 h with GSI-1 (at the concentrations 0.4, 0.8 and 1.2 mM) (D, left panel) bortezomib (2, 4, 6 nM) (D, middle panel) and MG132
(15, 30, 45 nM) (D, right panel). The percentage of the PI-negative cells was calculated as in (B). Points, mean (n=3); bars, SEM. *p-value,0.05
compared to cells transfected with scrambled oligonucleotide.
doi:10.1371/journal.pone.0029541.g002
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MyLa2000. Similar to SeAx cells, we observed an increase in the
number of apoptotic cells after GSI-1, bortezomib and MG132
treatment in miR-122 depleted cells relative to the scrambled
oligonucleotide control (Figure 2D). Taken together, our data
suggested that miR-122 conferred a protective response of
malignant T-cells to chemotherapy-induced apoptosis in CTCL.
miR-122 protects against apoptosis by activation of Akt
signalling
Our next aim was to determine which signalling pathways
involved in apoptosis are modulated by miR-122. It is known that
apoptosis in SeAx cells can be caused by the inhibition of Stat3 or
Akt signalling [8,33,34]. Overexpression of miR-122 did not
inhibit either Stat3 or NF-kB (data not shown). However, we
found that miR-122 overexpression induced Akt phosphorylation
at Ser
473 after 4 hours (,2 fold increase compared with control
siRNA) (Figure 3A). We confirmed the functional activation of Akt
in miR-122 overexpressing cells by showing that the downstream
targets of Akt, p70 S6K and Forkhead FOXO3a transcription
factor (FXHRL1), were phosphorylated (Figure 3A). The pro-
apoptotic drugs (GSI-1, bortezomib and MG132) decreased the
Akt phosphorylation (Figure 3A, B) and the simultaneous
treatment with miR-122 mimic and GSI-1 recovered Akt activity
(Figure 3A). These data indicated that miR-122 inhibited
apoptosis via activation of Akt. We further confirmed that Akt
activation was functional in the regulation of apoptosis by showing
that inhibition of PTEN, the major negative regulator of Akt,
protected the SeAx cells from GSI-1-induced cytotoxicity
(Figure 3C).
Interestingly, we observed a reciprocal regulation between miR-
122 and Akt. In addition to the above described activation of Akt
by miR-122, the inhibition of Akt activity by 2 different blockers,
Ly294002 (a potent inhibitor of phosphoinositide 3-kinases,
PI3Ks) and Akt Inhibitor X (inhibitor of the phosphorylation of
Akt and its in vitro kinase activity) induced expression of miR-122
in SeAx cells (Figure 3D). Notably, no miR-122 increase following
the Akt inhibition was observed in Hut-78 cells (Figure 3D).
miR-122 induction depends on p53
To elucidate whether the observed increase in miR-122 is a
direct consequence of Akt inhibition or is mediated by another
protein we focused on a possible role of p53. The idea that p53
might be involved arose from the observations in another T-cell
neoplasm, T-ALL, where hyperactivation of Notch-1 inhibits
PTEN, which in turn leads to activation of Akt and p53
degradation via induction of human homolog of the mouse double
minute 2 p53-binding protein (MDM2) (for a review see Dotto
[35]). We observed that GSI-1, bortezomib and MG132 induced
p53 accumulation in SeAx cells (Figure 4A, B) and that miR-122
mimic oligonucleotide inhibited this response (Figure 4B). Third,
Akt inhibition by Ly294002 and Akt Inhibitor X increased p53
(Figure 4C) and the activation of Akt by siRNA against PTEN
increased the phosphorylation of Ser
166 on MDM2 and caused a
degradation of p53 (Figure 4D).
To further investigate the role of p53 in apoptosis in CTCL we
used nutlin-3a that is a known inducer of p53 acting via disruption
of p53-MDM2 interaction [36]. Nutlin-3a amplified the apoptosis
induced by Akt inhibition (Figure 4E) and was also able to sensitize
SeAx cells to GSI-1, MG132 and bortezomib (Figure 4F).
However, the up-regulation of p53 by nutlin-3a did not change
the phosphorylation status of Akt (Figure S2A) and did not cause
apoptosis (Figure S2B). The down-regulation of p53 by a specific
siRNA (Figure S2C) did not affect Akt activation either (Figure
S2D). Thus, p53 modulated the sensitivity of SeAx cells to
apoptosis, but did not cause cell death on its own. This conclusion
was further reinforced by analysis of another CTCL cell line, Hut-
78. These cells have a mutated P53 (P53
mut) [37] and did not
accumulate p53 after nutlin-3a treatment (Figure 5A) and were
more resistant than SeAx to the apoptosis after treatment with
GSI-1, bortezomib and MG132 (Figure 5B).
The induction of miR-122 during apoptosis seemed to occur via
p53. In SeAx cells nutlin-3a led to p53 accumulation (Figure 5A)
and potently induced miR-122 (Figure 5C). In contrast, in Hut-78
cells, harbouring a truncated form of p53 [37], we observed
neither a stabilization of p53 nor up-regulation of miR-122 after
exposure to nutlin-3a (Figure 5A, C). Similarly, GSI-1, bortezomib
and MG132 induced p53 (Figure 4A, B) and miR-122 in SeAx
cells, but not in Hut-78 cells (Figure 1D). Therefore, we
determined whether the miR-122 up-regulation by chemothera-
pies was mediated by p53. p53 in SeAx cells was down-regulated
with siRNA and the cells were exposed for 24 h to GSI-1,
bortezomib, MG132 and doxorubicin. The expression of miR-122
was significantly up-regulated after the treatment in the control
cells transfected with scrambled oligonucleotide but not in the cells
in which p53 was silenced by siRNA (Figure 5D). In order to
examine whether the miR-122 modulation by p53 in SeAx cells
was mediated transcriptionally or post-transcriptionally, we used
qRT-PCR for examining changes in miR-122 primary transcript
(pri-miR-122) and mature form (mature miR-122) levels following
nutlin-3a exposure (Figure 5E). Time course analysis revealed no
significant change in pri-miR-122 (less than two-fold), but showed
an increased mature miR-122 expression upon nutlin-treatment.
Thus, we suggest that p53 modulation of miR-122 occurs post-
transcriptionally.
The results of our experiments led to a model of miR-122 action
outlined in Figure 6. Akt inactivation is a major effector pathway
in drug-induced apoptosis and cell death is additionally amplified
by p53. On the other hand, the p53 signalling leads to the
induction of miR-122, which is antiapoptotic via activation of Akt.
Discussion
This study shows for the first time that miR-122, previously
thought to be specific for liver, is expressed in vivo in lymphoma
cells in CTCL and is further induced during chemotherapy-
induced apoptosis. miR-122 expression is up-regulated in
advanced stage MF, which may be clinically relevant since the
tumour stage (T3) is associated with poor prognosis compared to
T2. In contrast to what has been observed in the liver, miR-122
protects against chemotherapy-induced cytotoxicity. The likely
mechanism by which miR-122 exerts its cytoprotective effect in
lymphoma cells involves p53 and Akt (Figure 6).
The Akt signalling is an important survival pathway essential for
the maintenance of malignant cell clones in different cancers,
including CTCL [33,38]. We have advanced the understanding of
the role of Akt in CTCL by showing an interplay between Akt and
p53. Akt inactivation induced p53 that amplified the pro-apoptotic
signal. However, p53 induction did neither provide a sufficient
signal for apoptosis nor could it change the phosphorylation status
of Akt in SeAx cells. A similar Akt-p53 regulatory circuit has been
described in T-ALL [35,39,40], and in other neoplasms as cervival
carcinogenesis [41]. We suggest that the P53 status might be an
important determinant of treatment outcomes for the lymphoma
chemotherapies that predominantly act via the Akt pathway.
Interestingly, P53 mutations are rare in cutaneous lymphomas,
and are found in very late stages during disease progression [42]
and p53 overexpression is associated with large-cell transformation
even in the absence of gene mutations [43].
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PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e29541miR-122 is a potent regulator of this pathway. Akt inactivation,
either directly by chemical antagonist (Akt Inhibitor X), by PI3K
blockers (Ly294002), or indirectly by chemotherapeutic agents
induced miR-122 expression. In turn, overexpression of miR-122
activated Akt and increased the resistance of the cells to apoptosis.
The detailed mechanism of miR-122 action remains unknown.
miR-122 affected the phosphorylation status of Akt but not the
amount of Akt protein, arguing against the possibility of direct
targeting. We could not detect any effect of miR-122 on the
essential upstream Akt kinase, PTEN, the regulatory subunit of
PI3K (p85a) or protein phosphatases such as PH domain leucine-
rich repeat protein phosphatase (PHLPP) (data not shown). The
Figure 3. Reciprocal regulation between miR-122 and Akt. A) miR-122 activates Akt signalling in SeAx cells. Immunoblots on whole cell-
lysates from scrambled siRNA (control) or miR-122 mimic-transducted cells exposed to GSI-1 (0.8 mM; 4 h) and probed for the indicated proteins of
the Akt signalling pathway. ß-actin was used as housekeeping gene, and relative protein expression levels are reported below the corresponding
western blot bands. The blots shown are representative from three independent experiments. B) Inhibition of Akt by bortezomib and MG132. SeAx
cells were treated with 6 nM bortezomib and 30 nM MG132 for 4 h and Akt activity was assessed in whole cell lysates by western blotting. C) Akt
activation protects against GSI-1-induced apoptosis. Decrease in apoptotic, annexin V positive cells in SeAx transfected with PTEN siRNA and exposed
to GSI-1 (1.2 mM, 24 h), comparing to the scrambled siRNA (control). Flow cytometry was done as described in Figure 2A. Graphs are representative of
three independent experiments. D) Akt inhibition induces miR-122 expression. qRT-PCR measurement of miR-122 level in SeAx and Hut-78 cells
treated with the indicated doses of Ly294002 and Akt inhibitor X for 24 h and expressed as fold change compared to those in the untreated cells.
Columns, mean (n=3); bars, SEM. * p-value,0.05 versus untreated cells.
doi:10.1371/journal.pone.0029541.g003
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e29541Figure 4. p53 amplifies the chemotherapy-induced apoptosis. A) p53 protein level was assessed by western blot analysis in SeAx cells treated
for 4 h with 6 nM bortezomib or 30 nM MG132. ß-actin was used as housekeeping gene, and relative p53 expression is reported as in Figure 3. B)
miR-122 mimic counteracts the GSI-1-induced p53 activation. Cells transfected with either a control siRNA or miR-122 mimic for 24 h were exposed to
GSI-1 for 4 h, at indicated concentrations. p53 expression was determined by western blot as in (A). C–D) Regulation of p53 by Akt. SeAx cells were
treated for 24 h with 20 mM Ly294002 or 10 mM Akt Inhibitor X (C) or transfected with PTEN or the scrambled, control siRNA (D). p53 was measured as
in (A). E–F) p53 activation by nutlin-3a increases the chemotherapy-induced apoptosis. SeAx were exposed to 5 or 10 mM nutlin-3a for 4 h followed
by 20 h treatment with Ly294002 (at the concentrations 10, 20 and 40 mM) (E) or GSI-1 (0.4, 0.8, 1.2 mM) (F, left panel)), bortezomib (2, 4, 6 nM) (F,
middle panel), MG132 (15, 30, 45 nM) (F, right panel). Cell viability was determined as in Figure 2. Points, mean (n=3); bars, SEM. * p-value,0.05,
versus untreated cells.
doi:10.1371/journal.pone.0029541.g004
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e29541latter was especially relevant, since the isoform PHLPP2 has been
predicted as a direct target of miR-122 using the computational
prediction tool miRanda (microRNA.org). However, we detected
an effect of miR-122 on a known direct target, cyclin G1 [24]. The
role of cyclin G1 is controversial, since it was shown to act as
oncogene [24,44] or tumour suppresor gene [45,46], depending
on cellular context and different experimental settings. According
to previous reports [24], a 1.7-fold decrease of cyclin G1 was
observed after miR-122 overexpression (data not shown).
The miR-122 induction depended on the presence of p53, as
chemotherapies failed to induce miR- 122 expression in P53
mut
Hut-78 cells and specific attenuation of endogenous p53 with
siRNA counteracted the miR-122 up-regulation by chemothera-
peutic agents in SeAx cells. However, the presence of high baseline
levels of miR-122 in Hut-78 cells suggests the existence of p53-
independent pathways of miR-122 regulation. These pathways
were not activated by the anticancer drugs tested in this study.
Our results suggest that targeting of miR-122 may improve the
outcome of chemotherapy in CTCL. miRNA-based therapy is a
rapidly developing field and this approach seems to be feasible in
the treatment of cancer [47,48]. Interestingly, the LNA-antimiR-
122 has been developed for the treatment of hepatitis C and has
shown efficacy after systemic administration in non-human
primates (Miravirsen, Santaris Pharma A/S) [49–51]. Miravirsen
has currently progressed into phase 2 clinical development to treat
patients with chronic hepatitis C. Our work provides a rationale
for the use of this drug as a chemotherapy sensitizer in therapy-
resistant CTCL.
Figure 5. miR-122 induction depends on p53. A) p53 immunoblots of whole-cell lysates from Hut-78 (P53
mut) and SeAx cells treated with nutlin-
3a (10 mM; 24 h). B) Dose-dependent effect of GSI-1 (at the concentrations 0.4, 0.6, 0.8, 1 and 1.2 mM), bortezomib (2, 4, 6, 8, 10 nM) and MG132 (20,
40, 60, 80, 100 nM) on apoptosis in SeAx and Hut-78 cell lines. Cell viability was determined as in Figure 2B. Points, mean (n=3); bars, SEM. * p-
value,0.05 versus untreated cells. C) Quantification of miR-122 expression by qRT-PCR in SeAx and Hut-78 cells treated with the indicated doses of
nutlin-3a for 24 h. miR-122 levels after treatment are expressed as fold change compared to the mock-treated cells as in Figure 1D. Columns, mean
(n=3); bars, SEM. * p-value,0.05, versus untreated cells. D) p53 siRNA counteracts the miR-122 induction in SeAx cells. qRT-PCR measurement of miR-
122 level in SeAx cells transfected with p53 siRNA or scrambled oligonucleotide and treated with 0.8 mM GSI-1, 30 nM MG132, 6 nM bortezomib and
1 mM doxorubicin for 24 h. Data show fold-changes in miR-122 level after treatment as compared to the control, mock-treated cells. Columns, mean
(n=3); bars, SEM. * p-value,0.05 versus untreated cells,
+ p-value,0.05 versus cells transfected with scrambled oligonucleotide. E) SeAx cells were
sampled at various time points during the exposure to 5 mM nutlin-3a and the expression of the mature miR-122 or miR-122 primary transcript (pri-
miR-122) was quantified by qRT-PCR. Points, mean (n=3); bars, SEM. * p-value,0.05, versus untreated cells.
doi:10.1371/journal.pone.0029541.g005
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Figure S1 Efficiency of miR-122 transfection evaluated
by quantitative RT-PCR. A-B) miR-122 level was quantified in
SeAx (A) or MyLa2000 cells (B) transfected with scrambled
(control), miR-122 mimic or antagomiR-122 oligonucleutides and
then exposed to 0.8 mM GSI-1 for 24 h. miR-122 expression is
normalized to the relative miR-122 level in the control sample.
Columns, mean (n=3).
(TIF)
Figure S2 Effect of p53 deregulation on Akt. A) Akt
activity in SeAx cells exposed to nutlin-3a (10 mM; 24 h) assessed
by western blotting. Relative expression of phosphorylated Akt is
reported as fold change using ß-actin as a housekeeping gene.
Representative of three independent experiments. B) Cell viability,
expressed as percentage of the PI-negative cells, was assessed in
SeAx cells exposed to nutlin-3a (2.5, 5, 10, 20 mM; 24) by flow
cytometry. Points, mean (n=3); bars, SEM. C) SeAx cells were
transfected with either scrambled (control) or p53 siRNA and then
exposed to nutlin-3a (10 mM) for 24 h. To measure p53 protein
level the cells were fixed in 70% ethanol overnight, permeabilized
with Triton X-100 and incubated with primary antibody against
p53 for 1 h at 37uC. p53 detection was assessed by a secondary
Alexa fluor 488-coniugated antibody. Cellular DNA was stained
with 7-amino-actinomycin D (7AAD; Beckman Coulter, Fullerton,
CA) and the amount of p53 was determined by flow cytometry in a
Cell Lab Quanta SC MPL flow cytometer. Nutlin-3a increased
p53 amount in the control sample but not in p53 siRNA-
transfected cells. D) Immunoblots on whole cell-lysates from
scrambled (control) or p53 siRNA-transfected cells probed for the
Akt phosphorylation status.
(TIF)
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